Organoid Models of Glioblastoma and Their Role in Drug Discovery

Matthew J. Rybin, Michael E. Ivan, Nagi G. Ayad, Zane Zeier

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastoma (GBM) is a devastating adult brain cancer with high rates of recurrence and treatment resistance. Cellular heterogeneity and extensive invasion of surrounding brain tissues are characteristic features of GBM that contribute to its intractability. Current GBM model systems do not recapitulate some of the complex features of GBM and have not produced sufficiently-effective treatments. This has cast doubt on the effectiveness of current GBM models and drug discovery paradigms. In search of alternative pre-clinical GBM models, various 3D organoid-based GBM model systems have been developed using human cells. The scalability of these systems and potential to more accurately model characteristic features of GBM, provide promising new avenues for pre-clinical GBM research and drug discovery efforts. Here, we review the current suite of organoid-GBM models, their individual strengths and weaknesses, and discuss their future applications with an emphasis on compound screening.

Original languageEnglish (US)
Article number605255
JournalFrontiers in Cellular Neuroscience
Volume15
DOIs
StatePublished - Feb 5 2021

Keywords

  • brain organoids
  • compound screening
  • drug discovery
  • glioblastoma
  • organoid-GBM modeling

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Organoid Models of Glioblastoma and Their Role in Drug Discovery'. Together they form a unique fingerprint.

Cite this